Amgen Inc. (NASDAQ:AMGN) ranks among the best low volatility stocks to buy according to analysts. While keeping its ...

"MariTide and all of the GLP-1 medications have similar side effect profiles: nausea, vomiting, abdominal pain, constipation and less commonly pancreatic irritation," says Dr. Nadler.

In the Phase 2 study, MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes (T2D) compared with 2.6% in the placebo arm, and up to ~17% average ...

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients ...

If MariTide achieves 22-23% weight loss in the phase 3 trial and CagriSema and retatrutide are in the 24-27% range which I estimated based on the available phase 2 data, I do not believe that the ...

MariTide did not appear to outperform its competitors significantly. Zepbound showed slightly better results, peaking at an average weight loss of around 25% after a year’s worth of dosage, while ...

This would greatly diminish MariTide's convenience advantage over the current drugs. However, they may be less effective. One study showed they reduced weight by only 9% to 13% after 26 weeks.

Amgen has said MariTide could offer quicker weight loss, possibly better weight maintenance, and fewer shots than weekly injections such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

MariTide is expected to be delivered as a single dose in a convenient, handheld, patient-friendly, autoinjector device with a monthly or less frequent single-injection administration.

MariTide's monthly or less frequent dosing has the potential to improve adherence and long-term weight control, providing the opportunity to optimize health outcomes for people living with obesity ...